Approximately 29% of Infants Receive RSV Immunization in the 2023-2024 Season
In the 2023-2024 season, nearly 30% of infants in the U.S. received RSV protection via vaccination or monoclonal antibodies, highlighting ongoing efforts to combat severe respiratory infections in newborns.
During the 2023-2024 respiratory virus season, about 29% of infants born between October 2023 and March 2024 in 33 U.S. states and the District of Columbia were immunized against respiratory syncytial virus (RSV). This coverage includes vaccinations administered through infant receipt of nirsevimab and maternal RSV vaccination during pregnancy. Researchers from the CDC, led by Ellen O. Boundy, estimated that 19% of infants received nirsevimab, a monoclonal antibody, while 10% were vaccinated maternally. Notably, 38% of infants given nirsevimab received it within the first week of life. The variation in immunization coverage among states ranged from 11% to 53%. These efforts aim to enhance protection for infants against severe RSV disease, although experts emphasize the need for increased immunization initiatives to better safeguard this vulnerable population.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Multiple Chronic Conditions Significantly Increase Depression Risk, Study Finds
A recent study reveals that individuals with multiple chronic health conditions, especially combinations like diabetes and heart disease, face more than double the risk of developing depression. Integrated care approaches are essential to address this complex health challenge.
New Research Finds Hepatitis C Virus in Human Brain Cell Lining
Recent findings reveal hepatitis C virus resides in the brain's lining, potentially impacting psychiatric disorders like schizophrenia and bipolar disorder. This breakthrough highlights the role of viral infections in mental health and opens new pathways for treatment.
Innovative Bioengineered Skin Accelerates Burn Healing in Preclinical Studies
A pioneering bioengineered skin developed by researchers from Tel Aviv University and Sheba Medical Center dramatically speeds up burn wound healing in preclinical models, offering new hope for improved burn treatments.
